{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:13:45Z","timestamp":1791299625410,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004610.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000}}],"reference-count":97,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004610.pub5","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T17:34:31Z","timestamp":1488562471000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Antibiotic treatment for <i>Clostridium difficile<\/i>\n-associated diarrhoea in adults"],"prefix":"10.1002","volume":"2017","author":[{"given":"Richard L","family":"Nelson","sequence":"first","affiliation":[{"name":"University of Illinois School of Public Health; Epidemiology\/Biometry Division; 1603 West Taylor Room 956 Chicago Illinois USA 60612"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J","family":"Suda","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago; Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlesnika T","family":"Evans","sequence":"additional","affiliation":[{"name":"Northwestern University; Department of Preventive Medicine and Center for Healthcare Studies; 633 N. St. Clair Chicago IL USA 60611"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD004610.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/00365549409011800","article-title":"Treatment of Clostridium difficile-associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group","volume":"26","author":"Anonymous","year":"1994","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004610.pub5-BIB0002|cit2","first-page":"74","article-title":"Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin","volume":"5","author":"Boero","year":"1990","journal-title":"Microbiologia Medica"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD004610.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/AAC.36.10.2192","article-title":"Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea","volume":"36","author":"Lalla","year":"1992","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD004610.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archinte.1986.00360180083015","article-title":"Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial","volume":"146","author":"Dudley","year":"1986","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0002-9343(89)90223-4","article-title":"Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens","volume":"86","author":"Fekety","year":"1989","journal-title":"American Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004610.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/jac\/dkr377","article-title":"A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection","volume":"66","author":"Garey","year":"2011","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD004610.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clinical Infectious Diseases"},{"issue":"6153","key":"10.1002\/14651858.CD004610.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/bmj.2.6153.1667","article-title":"Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea","volume":"2","author":"Keighley","year":"1978","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1086\/506354","article-title":"Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea","volume":"43","author":"Lagrottereria","year":"2006","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD004610.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/jac\/dkw246","article-title":"Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial","volume":"71","author":"Lee","year":"2016","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.01442-07","article-title":"Clinical outcomes, safety and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004610.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1128\/AAC.00504-15","article-title":"Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection","volume":"59","author":"Louie","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD004610.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1128\/AAC.04251-14","article-title":"Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections","volume":"59","author":"Mullane","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/506351","article-title":"Nitazoxanide for the treatment of Clostridium difficile colitis","volume":"43","author":"Musher","year":"2006","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/596552","article-title":"Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study","volume":"48","author":"Musher","year":"2009","journal-title":"Clinical Infectious Diseases"},{"issue":"8358","key":"10.1002\/14651858.CD004610.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(83)91036-X","article-title":"Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis","volume":"2","author":"Teasley","year":"1983","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","article-title":"Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea","volume":"22","author":"Wenisch","year":"1996","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/dkh278","article-title":"A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea","volume":"54","author":"Wullt","year":"2004","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/0016-5085(85)90206-9","article-title":"Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin","volume":"89","author":"Young","year":"1985","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD004610.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cct.2015.07.015","article-title":"Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial","volume":"44","author":"Barker","year":"2015","journal-title":"Contemporary Clinical Trials"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"s325","DOI":"10.1016\/S0016-5085(11)61320-6","article-title":"Comparison of nitazoxanide and vancomycin taper regimens as a salvage therapy for patients with recurrent mild to moderate Clostridium difficile infection (CDI)","volume":"140","author":"Basu","year":"2011","journal-title":"Gastroenteology"},{"issue":"3","key":"10.1002\/14651858.CD004610.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/jac\/dkv404","article-title":"Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection","volume":"71","author":"Brumley","year":"2016","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"9","key":"10.1002\/14651858.CD004610.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/apt.13144","article-title":"Randomised clinical trial: Faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection","volume":"41","author":"Cammarota","year":"2015","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"19","key":"10.1002\/14651858.CD004610.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.vaccine.2016.03.028","article-title":"Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized phase 2 clinical trial","volume":"34","author":"Bruyn","year":"2016","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0028|cit28","unstructured":"Forster AJ Daneman N van Walraven C Influence of antibiotics and case exposure on hospital-acquired Clostridium difficile infection independent of illness severity Journal of Hospital Infection 10.1016\/j.jhin.2016.10.007"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/jac\/dkv300","article-title":"Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection","volume":"71","author":"Gerding","year":"2016","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"7","key":"10.1002\/14651858.CD004610.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"A513","DOI":"10.1016\/j.jval.2016.09.964","article-title":"Cost-effectiveness analysis of fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in Egypt","volume":"19","author":"Hossam","year":"2016","journal-title":"Value in Health"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-117-4-297","article-title":"Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial","volume":"117","author":"Johnson","year":"1992","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0032|cit32","first-page":"1","article-title":"Does extending Clostridium difficile treatment in patients who are receiving concomitant antibiotics reduce the rate of relapse?","volume":"15","author":"Kaki","year":"2016","journal-title":"Internet Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004610.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.18098","article-title":"Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: A randomized clinical trial","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"Article Number:","DOI":"10.1155\/2016\/8048757","article-title":"Fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: Canadian outcomes","volume":"2016","author":"Lee","year":"2016","journal-title":"Canadian Journal of Infectious Diseases and Medical Microbiology"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/506349","article-title":"Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea","volume":"43","author":"Louie","year":"2006","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004610.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMoa0907635","article-title":"Treatment with monoclonal antibodies against Clostridium difficile toxins","volume":"362","author":"Lowy","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004610.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1080\/00365540801964960","article-title":"A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety of a prematurely interrupted trial","volume":"40","author":"Mattila","year":"2008","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD004610.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD004610.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.bbmt.2015.11.537","article-title":"Outcomes of deflect-1: A multicenter, blinded, randomized clinical trial of fidaxomicin (FDX) vs. placebo (PLC) for prophylaxis of Clostridium difficile-associated diarrhea (CDAD) in subjects undergoing hematopoietic stem cell transplantation (HSCT)","volume":"22","author":"Mullane","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD004610.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1128\/AAC.00019-06","article-title":"Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid","volume":"50","author":"Noren","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD004610.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/gut.2006.119016","article-title":"Clostridium difficile-associated diarrhoea: bovine anti-clostridium difficile whey protein to help aid the prevention of relapses","volume":"56","author":"Numan","year":"2007","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD004610.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijantimicag.2015.03.016","article-title":"Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection","volume":"46","author":"Thabit","year":"2015","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"12","key":"10.1002\/14651858.CD004610.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ajic.2016.05.027","article-title":"Effect of an antimicrobial stewardship intervention on outcomes for patients with Clostridium difficile infection","volume":"44","author":"Welch","year":"2016","journal-title":"American Journal of Infection Control"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD004610.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1016\/S0016-5085(12)62296-3","article-title":"The efficacy and safety of rifaximin vs. vancomycin in the treatment of mild to moderate C. difficile infection: A randomized double-blind active comparator trial","volume":"142","author":"Pardi","year":"2012","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD004610.pub5-BIB0045|cit45","first-page":"259","article-title":"Oral vancomycin plus intravenous metronidazole versus oral vancomycin in severe Clostridium difficile-associated diarrhea: a single center study","volume":"34","author":"Shyh","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0046|cit46","unstructured":"NCT01983683 A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile -associated diarrhea (CDAD) clinicaltrials.gov\/ct2\/show\/NCT01983683"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0047|cit47","unstructured":"NCT01987895 A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile -associated diarrhea (CDAD) clinicaltrials.gov\/ct2\/show\/NCT01987895"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0048|cit48","unstructured":"Minnesota Evidence-based Practice Center Early diagnosis, prevention and treatment of Clostridium difficile: Update AHRQ Publication No. 16-EHC012-EF March, 2016 1 37"},{"issue":"9209","key":"10.1002\/14651858.CD004610.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1001\/jama.2014.17103","article-title":"Diagnosis and treatment of Clostridium difficile in adults: a systematic review","volume":"313","author":"Bagdasarian","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-2-13","article-title":"The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?","volume":"2","author":"Baker","year":"2002","journal-title":"BMC Medical Research Methodology"},{"issue":"11 Suppl","key":"10.1002\/14651858.CD004610.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1093\/ajcn\/33.11.2521","article-title":"Clinical and laboratory observations in Clostridium difficile colitis","volume":"33","author":"Bartlett","year":"1980","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1093\/clinids\/12.Supplement_2.S243","article-title":"Clostridium difficile: clinical considerations","volume":"12 Suppl 2","author":"Bartlett","year":"1990","journal-title":"Reviews of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMcp011603","article-title":"Clinical practice. Antibiotic-associated diarrhea","volume":"346","author":"Bartlett","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004610.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1469-0691.2009.03099.x","article-title":"European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance for Clostridium difficile infection (CDI)","volume":"15","author":"Bauer","year":"2009","journal-title":"Clinical Microbiology and Infection"},{"issue":"12","key":"10.1002\/14651858.CD004610.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1086\/523720","article-title":"Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea","volume":"45","author":"Bishara","year":"2007","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0057|cit57","first-page":"178","article-title":"Pseudomembranous enterocolitis: mechanism for restoring floral homeostasis","volume":"47","author":"Bowden","year":"1981","journal-title":"American Surgeon"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infection Control and Hospital Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bjid.2015.03.006","article-title":"A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity","volume":"19","author":"Di","year":"2015","journal-title":"Brazilian Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD004610.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"839","DOI":"10.7326\/0003-4819-155-12-201112200-00007","article-title":"Comparative effectiveness of Clostridium difficile treatments: a systematic review","volume":"155","author":"Drekonja","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.1993.03500010081036","article-title":"Diagnosis and treatment of Clostridium difficile colitis","volume":"269","author":"Fekety","year":"1993","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0062|cit62","first-page":"739","article-title":"Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis","volume":"92","author":"Fekety","year":"1997","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(07)61604-3","article-title":"Non-inferiority trials are unethical because they disregard patients' interests","volume":"370","author":"Garattini","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD004610.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1128\/jcm.15.6.1049-1053.1982","article-title":"Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions","volume":"15","author":"George","year":"1982","journal-title":"Journal of Clinical Microbiology"},{"issue":"8","key":"10.1002\/14651858.CD004610.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2307\/30141083","article-title":"Clostridium difficile-associated diarrhea and colitis","volume":"16","author":"Gerding","year":"1995","journal-title":"Infection Control and Hospital Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD004610.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.295.10.1172","article-title":"Lessons from and cautions about noninferiority and equivalence randomized trials","volume":"295","author":"Gotzsche","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0067|cit67","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0068|cit68","unstructured":"Johns Hopkins Teicoplanin www.hopkins-abxguide.org\/antibiotics\/antibacterial\/glycopeptide\/teicoplanin.html?contentInstanceId=254836 2009"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0069|cit69","unstructured":"Health Protection Agency of the Department of Health UK Clostridium difficile infection: How to deal with the problem www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/340851\/Clostridium_difficile_infection_how_to_deal_with_the_problem.pdf"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0070|cit70","unstructured":"Health Protection Agency Deaths involving Clostridium difficile or MRSA, Wales: 2015 www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsinvolvingclostridiumdifficilewales\/2015"},{"issue":"8","key":"10.1002\/14651858.CD004610.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00605-12","article-title":"Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea","volume":"56","author":"Johnson","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2010.03.025","article-title":"A review of mortality due to Clostridium difficile infection","volume":"61","author":"Karas","year":"2010","journal-title":"Journal of Infection"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJM199401273300406","article-title":"Clostridium difficile colitis","volume":"330","author":"Kelly","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MCG.0b013e3181c87e02","article-title":"Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea","volume":"44","author":"Khoruts","year":"2010","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0075|cit75","unstructured":"Laurence J Deaths from \"dirty hospital bug\" double in five years The Independant 11"},{"issue":"9","key":"10.1002\/14651858.CD004610.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004610.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01831-13","article-title":"Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections","volume":"58","author":"Locher","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"9","key":"10.1002\/14651858.CD004610.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1503\/cmaj.051212","article-title":"How should we respond to the highly toxogenic NAP1\/ribotype 027 strain of Clostridium difficile?","volume":"173","author":"Louie","year":"2005","journal-title":"Canadian Medical Association Journal"},{"issue":"23","key":"10.1002\/14651858.CD004610.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004610.pub5-BIB0080|cit80","first-page":"439","article-title":"Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo","volume":"90","author":"McFarland","year":"1995","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD004610.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1128\/AAC.00021-14","article-title":"Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile","volume":"58","author":"Miesel","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1345\/aph.1M696","article-title":"The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea","volume":"44","author":"Novell","year":"2010","journal-title":"Annals of Pharmacotherapy"},{"issue":"9","key":"10.1002\/14651858.CD004610.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1503\/cmaj.050978","article-title":"Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec","volume":"173","author":"Pepin","year":"2005","journal-title":"Canadian Medical Association Journal"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/AAC.35.1.208","article-title":"Prosepctive study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery","volume":"35","author":"Privitera","year":"1991","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"9","key":"10.1002\/14651858.CD004610.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3201\/eid1309.061116","article-title":"Increase in Clostridium difficile-related mortality rates, United States, 1999-2004","volume":"13","author":"Redelings","year":"2007","journal-title":"Emerging Infectious Diseases"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0086|cit86","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"Available from www.cochrane-handbook.org, 2011"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0087|cit87","first-page":"g6284","article-title":"Multiple hypothesis testing and Bonferroni's correction","volume":"349","author":"Sedgwick","year":"2014","journal-title":"BMJ (Clinical research ed.)"},{"issue":"6","key":"10.1002\/14651858.CD004610.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/ije\/dyq136","article-title":"Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials.","volume":"39","author":"Soonawala","year":"2010","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD004610.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2004.11.004","article-title":"Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea","volume":"128","author":"Sougioultzis","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD004610.pub5-BIB0090|cit90","first-page":"1","article-title":"HCUP projections: Clostridium difficile hospitalizations","volume":"02","author":"Steiner","year":"2015","journal-title":"HCUP Projections Report"},{"issue":"7","key":"10.1002\/14651858.CD004610.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/codi.12134","article-title":"Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review","volume":"15","author":"Stewart","year":"2013","journal-title":"Colorectal Disease"},{"issue":"6","key":"10.1002\/14651858.CD004610.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/jac\/dkg254","article-title":"Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review","volume":"51","author":"Thomas","year":"2003","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD004610.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"Nood","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2012.01.004","article-title":"Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence","volume":"40","author":"Vardakas","year":"2012","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"1","key":"10.1002\/14651858.CD004610.pub5-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004610.pub2","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhea in adults","author":"Bricker","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004610.pub5-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004610.pub3","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhea in adults","author":"Nelson","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD004610.pub5-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004610.pub4","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhea in adults","author":"Nelson","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004610.pub5\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T09:50:20Z","timestamp":1686390620000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004610.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":97,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004610.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}